Nathaly Arndtz

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine

Jens Vollmar, Nathaly Arndtz, Karl M. Eckl et al. · Vaccine · 2005 · 170 citations

Vaccination, Vaccine Safety, Vaccine Development +8

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

Juan Dupont, Javier Altclas, Alejandro Lepetic et al. · Vaccine · 2006 · 65 citations

Vaccination, Vaccine Safety, Infectious Disease Prevention +8

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

Ralf G. Meyer, Cedrik M. Britten, U. Siepmann et al. · Cancer Immunology Immunotherapy · 2004 · 65 citations · Full text

Vaccination, Vaccine Development, Melanoma +9

Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene®) in healthy adults

I. Rebedea, Iulian Diaconescu, Doris Bach et al. · Vaccine · 2006 · 21 citations

Vaccination, Vaccinology, Vaccine Development +9

Immunization of Patients with Malignant Melanoma with Autologous CD34 ⁺ Cell-Derived Dendritic Cells Transduced <i>Ex Vivo</i> with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

Massimo Di Nicola, Carmelo Carlo‐Stella, Andrea Anichini et al. · Human Gene Therapy · 2003 · 21 citations